Skip to main content
. 2017 May 30;12:1613–1624. doi: 10.2147/COPD.S132709

Table S2.

Comparison of baseline characteristics according to pathology of lung cancer

Adenocarcinoma Squamous cell carcinoma Small cell carcinoma Undiagnosed
Patients, n 9 4 3 5
Gender, female, n (%) 1 (11.1) 0 (0) 1 (33.3) 0 (0)
Age, years 70.8±8.4 76.5±6.2 72.0±7.5 76.6±4.6
Smoking index, pack-years 61.6±20.0 65.9±28.5 48.2±14.0 78.1±49.2
Current smokers, n (%) 0 (0) 1 (25.0) 0 (0) 0 (0)
Previous history of extra-pulmonary cancer, n (%) 1 (11.1) 1 (25.0) 1 (33.3) 2 (40.0)
%FEV1 73.9±19.4 49.1±19.4 64.8±25.7 66.9±25.1
COPD grades 1/2/3/4, n 4/3/2/0 0/3/0/1 1/1/1/0 2/1/2/0
Blood examination
 Leukocytes, ×109/L 7.3±1.6 6.8±2.1 9.2±0.3 6.4±0.7
 CRP, mg/dL 0.4±0.3 0.6±0.8 0.5±0.5 0.1±0.1
 SAA/μg/mL 12.0±11.1 16.3±12.4 33.4±23.8 75.6±129.1
 CEA/ng/mL 28.3±57.6 4.1±0.8 4.4±0.4 5.3±3.5
 Pro-GRP/pg/mL 45.5±9.9 51.8±19.2 73.4±7.3 102.7±32.7
 CYFRA/ng/mL 2.2±1.4 2.5±2.0 3.2±2.3 3.9±2.8
Clinical stage of NSCLC
 I/II/III/IV/unknown, n 6/0/2/1/0 1/1/1/1/0 3/0/0/0/2
Clinical stage of SCLC LD/ED 1/2
Location of primary mass
 Upper/middle/lower lobes, n 6/0/3 1/0/3 0/1/2 1/2/2
Diagnosis and annual follow-up
 Chest CT/other extra causes, n 8/1 4/0 1/2 4/1
Treatment
 Operation/radiation/chemotherapy + radiation/chemotherapy/best supportive care, n 5/0/1/2/1 0/1/0/2/1 0/0/0/3/0 0/1/0/0/4

Note: Data are presented as n, mean ± SD, or n (%).

Abbreviations: %FEV1, percent predicted forced expiratory volume in 1 second; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; SAA, serum amyloid A; CEA, carcinoembryonic antigen; pro-GRP, pro-gastrin-releasing peptide; CYFRA, cytokeratin-19 fragments; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; LD, limited disease; ED, extensive disease; CT, computed tomography; SD, standard deviation.